Wednesday, May 11, 2016
07:00 - 08:00  
08:00 - 08:15

Welcome and Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

Words of Welcome

Overview of Today’s Sessions

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

08:15 - 09:45

BRCA biology and gene variants

CHAIR: Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

ClinGen and ClinVar: A new approach to gene variant data

Sharon E. Plon, MD, PhD, FACMG, Baylor College of Medicine, Houston, TX, USA

BRCA1/2 VUS: what’s new in variant classification?

David Goldgar, PhD, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA

Proffered Paper 1 : Massively parallel experimental analysis of missense mutations in BRCA1 for interpreting variants of uncertain significance

Lea Starita, PhD, Genome Sciences, Shendure Lab, University of Washington, Seattle, WA, USA

Proffered Paper 2 : Studying the functionality of the homologous repair pathway in zebrafish embryos: heading for an in vivo functional test to evaluate the pathogenicity of BRCA2 variants

Jeroen Vierstraete, Jeroen Vierstraete, Center for Medical Genetics Ghent (CMGG), Ghent University, Ghent, Belgium

Proffered Paper 3 : Sharing BRCA1 and BRCA2 data across Canada: a case study from the Canadian Open Genetics Repository

Matthew Lebo, PhD, FACMG, Lebo, PhD, FACMG, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Question and discussion period (all speakers)

09:45 - 10:15  
10:15 – 11:45

Implications of DNA defects on the cancer phenotype and management of BRCA mutated cancers

CHAIR: David Goldgar, PhD, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA

PolQ and its potential therapeutic implications for BRCA related cancer

Agnel Sfeir, PhD, Skirball Institute, New York University, New York, NY, USA

Pathology of hereditary ovarian cancers, with a focus on those features related to DNA repair deficiency

Blake Gilks, PhD, Professor, Dept of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

Proffered Paper 1 : Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study of men with BRCA mutations

Ros Eeles, FMedSci, MA, PhD, FRCR, FRCP, Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, UK

Proffered Paper 2 : DNA repair independent mechanisms mediating drug response in BRCA2 cancer

Sharon Cantor, PhD, Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA

Question and discussion period (all speakers)


11:45 - 13:15  

13:15 - 14:45

BRCA-related ovarian cancer: origins, diagnosis and outcome

CHAIR: Ronny Drapkin, MD, PhD, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA

Origins of BRCA-related ovarian cancer

Ronny Drapkin, MD, PhD, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA

BRCA1/2 germline mutations in acquired resistance and long term survival

David Bowtell, PhD, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia

Proffered Paper 1 : Systematic BRCA1/BRCA2 genetic testing in unselected epithelial ovarian cancer - results from the GTEOC study

Marc Tischkowitz, MD, PhD, Department of Medical Genetics, University of Cambridge, Cambridge, UK

Proffered Paper 2 : Hormone replacement therapy after risk-reducing salpingo-oophorectomy: significantly decreased postmenopausal symptoms in a prospective study

Ravi Vermeulen, MD, Gynaecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Proffered Paper 3 : Missense c.680C>T RAD51D variant confers predisposition to high grade serous ovarian cancer but not to breast cancer in the French Canadian population.

Barbara Rivera, PhD, Department of Human Genetics, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada

Question and discussion period (all speakers)

    (with break)
14:45 - 16:30
16:30 - 18:00

Special Debate: This house considers that population-based BRCA1/2 testing should be implemented

MODERATOR: Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

For the motion:

Steven Narod, MD, FRCPC, Canada Research Chair in Breast Cancer, Women’s College Research Institute/University of Toronto, Toronto, ON, Canada

Against the motion:

Nicoline Hoogerbrugge, MD, PhD, Radboud University Medical Center, Department of Human Genetics, Nijmegen, The Netherlands